Indiplon

Summary

Indiplon (CHEMBL262075) is a phase-3 clinical-stage small molecule targeting GABRA1; indicated across 2 conditions including insomnia and depressive disorder.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Targets: 1 (GABRA1)
• Indications: 2 conditions
• Clinical trials: 2
• Chemistry: 376.4 Da · C20H16N4O2S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL262075
Name	Indiplon
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	6450813
Molecular formula	C20H16N4O2S
Molecular weight	376.4
InChIKey	CBIAWPMZSFFRGN-UHFFFAOYSA-N

SMILES: CC(=O)N(C)C1=CC=CC(=C1)C2=CC=NC3=C(C=NN23)C(=O)C4=CC=CS4

IUPAC name: N-methyl-N-[3-[3-(thiophene-2-carbonyl)pyrazolo[1,5-a]pyrimidin-7-yl]phenyl]acetamide

Also known as: Calenthys, CL-285489, Indiplon, Indiplone, NBI-34060, INDIPLON, SID174006212, indiplon

Patent coverage: 682 distinct patent families (2,851 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 2,850 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
GABRA1	GABAA receptor α1 subunit	Full agonist		0%	P14867

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Gamma-aminobutyric acid receptor subunit alpha-1.

Bioactivity

ChEMBL activities: 2 potent at pChembl ≥ 5 of 2 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P62813	9.35	Ki	0.45	nM	CHEMBL_ACT_2133537
P62813	9.26	Ki	0.55	nM	CHEMBL_ACT_2133536

Target pathways

Aggregated over 1 target gene(s): GABRA1.

Top Reactome pathways

2 total, by targets touching each:

Pathway	Targets	Genes
Signaling by ERBB4	1	GABRA1
GABA receptor activation	1	GABRA1

Dominant GO biological processes

GO term	Targets
gamma-aminobutyric acid signaling pathway	1
synaptic transmission, GABAergic	1
chloride transmembrane transport	1
inhibitory synapse assembly	1
monoatomic ion transport	1
chloride transport	1
monoatomic ion transmembrane transport	1
regulation of postsynaptic membrane potential	1

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
insomnia	3	MONDO:0013600	EFO:0004698
depressive disorder	3	MONDO:0002050	MONDO:0002050

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE3	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00232167	PHASE3	TERMINATED	Study Of Indiplon/Placebo With Sertraline In Insomnia Co-Existing With Depression
NCT00525941	PHASE3	WITHDRAWN	An Exploratory Study of NBI-34060 Capsules and Next Day Functioning

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

71 molecules share ≥1 primary target. Top 60 by shared-target count:

Molecule	Source	Status	Shared targets
ALPRAZOLAM	ChEMBL	Phase 4 (approved)	GABRA1
APALUTAMIDE	ChEMBL	Phase 4 (approved)	GABRA1
ASENAPINE	ChEMBL	Phase 4 (approved)	GABRA1
AZELASTINE	ChEMBL	Phase 4 (approved)	GABRA1
BENPERIDOL	ChEMBL	Phase 4 (approved)	GABRA1
BREXANOLONE	ChEMBL	Phase 4 (approved)	GABRA1
CANDESARTAN CILEXETIL	ChEMBL	Phase 4 (approved)	GABRA1
CHLORAMBUCIL	ChEMBL	Phase 4 (approved)	GABRA1
CHLORDIAZEPOXIDE	ChEMBL	Phase 4 (approved)	GABRA1
CLONAZEPAM	ChEMBL	Phase 4 (approved)	GABRA1
CLOZAPINE	ChEMBL	Phase 4 (approved)	GABRA1
CRIZOTINIB	ChEMBL	Phase 4 (approved)	GABRA1
DIAZEPAM	ChEMBL	Phase 4 (approved)	GABRA1
ENZALUTAMIDE	ChEMBL	Phase 4 (approved)	GABRA1
EPINASTINE	ChEMBL	Phase 4 (approved)	GABRA1
ESZOPICLONE	ChEMBL	Phase 4 (approved)	GABRA1
ETOMIDATE	ChEMBL	Phase 4 (approved)	GABRA1
FLUMAZENIL	ChEMBL	Phase 4 (approved)	GABRA1
FLUNITRAZEPAM	ChEMBL	Phase 4 (approved)	GABRA1
GANAXOLONE	ChEMBL	Phase 4 (approved)	GABRA1
GLAFENINE	ChEMBL	Phase 4 (approved)	GABRA1
LINDANE	ChEMBL	Phase 4 (approved)	GABRA1
LIOTHYRONINE	ChEMBL	Phase 4 (approved)	GABRA1
PROPOFOL	ChEMBL	Phase 4 (approved)	GABRA1
SIMVASTATIN	ChEMBL	Phase 4 (approved)	GABRA1
STIRIPENTOL	ChEMBL	Phase 4 (approved)	GABRA1
TIPRANAVIR	ChEMBL	Phase 4 (approved)	GABRA1
TRIAZOLAM	ChEMBL	Phase 4 (approved)	GABRA1
TROGLITAZONE	ChEMBL	Phase 4 (approved)	GABRA1
ZALEPLON	ChEMBL	Phase 4 (approved)	GABRA1
ZOLPIDEM	ChEMBL	Phase 4 (approved)	GABRA1
ZURANOLONE	ChEMBL	Phase 4 (approved)	GABRA1
ALISERTIB	ChEMBL	Phase 3	GABRA1
GABOXADOL	ChEMBL	Phase 3	GABRA1
SURAMIN	ChEMBL	Phase 3	GABRA1
TIRATRICOL	ChEMBL	Phase 3	GABRA1
ALFAXALONE	ChEMBL + PubChem	Phase 2 (approved)	GABRA1
ABECARNIL	ChEMBL	Phase 2	GABRA1
ALOGABAT	ChEMBL	Phase 2	GABRA1
AZD7325	ChEMBL	Phase 2	GABRA1
BAICALEIN	ChEMBL	Phase 2	GABRA1
BASMISANIL	ChEMBL	Phase 2	GABRA1
BRETAZENIL	ChEMBL	Phase 2	GABRA1
DARIGABAT	ChEMBL	Phase 2	GABRA1
DELORAZEPAM	ChEMBL	Phase 2	GABRA1
FLAVONE	ChEMBL	Phase 2	GABRA1
LORECLEZOLE	ChEMBL	Phase 2	GABRA1
MK-0777	ChEMBL	Phase 2	GABRA1
PANADIPLON	ChEMBL	Phase 2	GABRA1
PIPERINE	ChEMBL	Phase 2	GABRA1
PROGABIDE	ChEMBL	Phase 2	GABRA1
REDAFAMDASTAT	ChEMBL	Phase 2	GABRA1
SARIPIDEM	ChEMBL	Phase 2	GABRA1
ZOTEPINE	ChEMBL	Phase 2	GABRA1
Afatinib	PubChem	Approved	GABRA1
Apixaban	PubChem	Approved	GABRA1
Binimetinib	PubChem	Approved	GABRA1
chenodiol	PubChem	Approved	GABRA1
Fulvestrant	PubChem	Approved	GABRA1
gentian violet	PubChem	Approved	GABRA1